Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

In CCC v AAC [2025] HKCFI 2987, Sir William Blair, sitting as Deputy High Court Judge in the Hong Kong Court of First Instance (“Court”), rejected ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

Detailed price information for Booz Allen Hamilton Holding Corp (BAH-N) from The Globe and Mail including charting and trades.

William Blair analysts lowered their rating on Ameriprise stock to Market Perform from Outperform Friday following the financial services firm’s second-quarter report.